A pilot clinical trial to monitor response to chemotherapy using the Ca-62 marker of epithelial carcinomas

The objective of the study was to assess the feasibility of using CA-62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy. Material and Methods. A 12-month double-blind clinical trial was conducted by two independent groups: clinical oncologists and biochemists, and involved 89 patients with different cancers confirmed by histopathological findings. The other inclusion criteria were: the presence of at least one measurable lesion according to the RECIsT criteria, ECOG performance status 0-2 and satisfactory laboratory parameters. The expression of CA-62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas. Results. The elevated level of CA-62 marker was observed in 76 patients before starting the treatment. After completion chemotherapy, the level of this marker decreased to the normal reference ranges (